Specify a stock or a cryptocurrency in the search bar to get a summary
Trevena Inc
TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. Address: 955 Chesterbrook Boulevard, Chesterbrook, PA, United States, 19087
Analytics
WallStreet Target Price
100 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TRVN
Dividend Analytics TRVN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TRVN
Stock Valuation TRVN
Financials TRVN
Results | 2019 | Dynamics |